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Cutaneous melanoma, the most common form of melanoma, is a 
complex disease that arises through multiple etiological pathways. 
The  cyclin-dependent  kinase  inhibitor  2A  (CDKN2A)  gene 
(Mendelian Inheritance in Man 600160), located on chromosome 
9p21, is known to be a major high–risk melanoma susceptibility 
gene that is transmitted according to a dominant mode of inheri-
tance in melanoma-prone families (1,2). It encodes two distinct 
tumor suppressor proteins that are translated in alternative reading 
frames (ARFs) from alternate spliced transcripts (3–6). The alpha 
(a)  transcript,  comprises  exons  1a,  2,  and  3  and  encodes  the 
p16INK4a protein. This protein is known to inhibit the cyclin-
dependent kinase 4 (CDK4)–mediated phosphorylation of retino-
blastoma 1 protein and prevents the cell from progressing through 
the G1 cell cycle checkpoint (3,4). The beta (b) transcript, com-
prises exons 1b, 2, and 3 and encodes the p14ARF protein. This 
protein acts via tumor protein p53 pathway to induce cell cycle 
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arrest or apoptosis (5,6). The germline CDKN2A mutations have 
been  found  in  about  40%  of  melanoma-prone  families  from 
around  the  world  (7).  Most  CDKN2A  mutations  are  scattered 
through the lengths of exons 1a and 2, thus affecting p16INK4a 
protein alone or both p16INK4a and p14ARF proteins (7). The 
penetrance  of  CDKN2A  mutations  in  multiple-case  melanoma 
families was found to vary across continents, indicating that varia-
tions  in  genetic  backgrounds,  host  characteristics,  and/or  sun 
exposure may contribute to the differences in penetrance (8).
Among the host phenotypes that may influence melanoma risk, 
dysplastic nevi, high numbers of banal nevi, poor tanning ability, 
and/or propensity to sunburn were shown to be associated with 
enhanced  CDKN2A  penetrance  in  melanoma-prone  families 
(9,10).  The  melanocortin-1  receptor  (MC1R)  gene  (Mendelian 
Inheritance in Man 155555), which plays a key role in the pigmen-
tation process (11), has been consistently found to be a low-risk 
melanoma susceptibility gene in case–control studies, discussed in 
a review article (12). Moreover, MC1R variants have been shown 
to increase melanoma risk in families with CDKN2A mutations 
(13–16).
The  MC1R  gene  is  highly  polymorphic  in  populations  of 
European  ancestry  and  more  than  85  nonsynonymous  variants 
have  been  identified  (17,18).  These  include  the  red  hair  color 
(RHC) variants that are consistently associated with red hair, light 
skin, poor tanning ability, and heavy freckling, and the non-RHC 
(NRHC)  variants  that  have  a  weaker,  or  no  association,  with   
red hair (19). In previous studies investigating the associations of 
MC1R  variants  with  melanoma,  whether  conducted  in  case–
control series or melanoma-prone families, the melanoma risk was 
mainly associated with the RHC variants, although it has also been 
reported to be influenced by certain NRHC variants (12,13–16), 
indicating  that  MC1R  plays  a  role  in  melanoma  development 
beyond that of pigmentation. Moreover, an increase in melanoma 
risk  with  an  increase  in  number  of  MC1R  variants  has  been 
reported in most (12,14–16), but not all (13,20), studies.
To date, there are limited investigations on the joint associa-
tions of MC1R variants, pigmentation, and nevus phenotypes, with 
melanoma risk in CDKN2A mutation carriers. Two studies (15,16) 
explored these joint associations (MC1R variants and pigmentation 
phenotypes, or MC1R variants and nevus phenotypes, or MC1R 
variants and pigmentation phenotypes and nevus phenotypes) but 
were conducted in relatively small number of CDKN2A mutation 
carriers. The joint associations of MC1R variants, pigmentation 
phenotypes, and/or nevus phenotypes with melanoma risk were 
tested  in  one  study,  but  were  restricted  to  RHC  variants  (16). 
Moreover, it is not known whether the associations of MC1R var-
iants with melanoma risk in CDKN2A carriers vary, depending on 
whether the CDKN2A mutation alters p16INK4A protein alone or 
both p16INK4A and p14ARF proteins. Furthermore, MC1R vari-
ants have been inconsistently associated with a reduction in age at 
diagnosis of melanoma in CKDN2A mutation carriers (13–16).
The  Melanoma  Genetics  Consortium  (GenoMEL),  which 
includes major familial melanoma research groups from Europe, 
North America, and Australia, has recruited the largest sample of 
CDKN2A mutation carriers, to our knowledge, to assess the asso-
ciation of MC1R variants with melanoma risk. In this study, we 
analyzed  815  CDKN2A  mutation  carriers  that  participated  in 
GenoMEL to assess the association of MC1R variants, alone or in 
combination with host phenotypes, with melanoma risk in white 
populations  with  varying  pigmentation  characteristics  and  from 
countries  and  continents  located  at  different  latitudes  with  dif-
ferent patterns of sun exposure. We also explored whether the as-
sociation  of  MC1R  variants  with  melanoma  risk  differed  if  the 




Fifteen  GenoMEL  centers  from  Europe,  North  America,  and 
Australia participated in the present analyses (Appendix). The fol-
lowing geographic locales were defined across three continents: 
Europe—France (Paris), Italy (Emilia-Romagna and Genoa), the 
Netherlands  (Leiden),  Spain  (Barcelona),  Sweden  (Lund, 
Stockholm),  and  United  Kingdom  (Glasgow,  Leeds);  North 
America—Boston, NCI, Philadelphia, and Toronto; Australia—
Brisbane and Sydney. Individual country locales were only consid-
ered within Europe in the analyses.
The CDKN2A mutation carriers from families with at least two 
cutaneous melanoma patients and presence of a germline CDKN2A 
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The  association  between  cyclin-dependent  kinase  inhibitor  2A 
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influenced  by  host  phenotypes  (hair  color,  sunburn,  number  of 
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mutation in the family were eligible for the study. The types of 
CDKN2A  mutations  identified  in  the  families  included  in  this 
study  are  shown  in  Supplementary  Table  1  (available  online). 
Diagnoses of melanoma were confirmed by review of histology and 
pathology reports, medical records, or death certificates. To be 
eligible for the study, family members also had to have been geno-
typed for MC1R; approximately 94.2% of the CDKN2A mutation 
carriers were genotyped at the MC1R locus and were included in 
the analyses. For each continent, we checked whether the CDKN2A 
mutation  carriers  who  were  genotyped  or  not  genotyped  for 
MC1R differed in terms of melanoma affection status, sex, and age 
at examination and found that there was no difference (data not 
shown). Table 1 presents the total number of participants from 
186 families (N = 815; 473 melanoma patients [affected], and 342 
unaffected relatives with no manifestation of melanoma at the time 
the study was initiated) who were genotyped at the CDKN2A and 
MC1R loci by the GenoMEL study centers. The degree of familial 
relationship was estimated by examining all possible pairs of af-
fected and unaffected subjects within families and their distribution 
was as follows—22% of affected and unaffected pairs were first-
degree  relatives,  23%  were  second-degree  relatives,  20%  were 
third-degree relatives, and the remaining 35% were more remote 
relatives. For all centers, written informed consent was obtained 
from all subjects before recruitment under an Institutional Review 
Board–approved protocol. Although the process of identifying and 
recruiting families differed among the GenoMEL centers because 
of variation in local health-care procedures and/or approaches for 
accruing families, the eligibility criteria for inclusion in this study 
were uniform, as described above. Details of the participating fam-
ilies and data collection have been described elsewhere (see Table 1 
for references).
Genotyping of CDKN2A and MC1R
The protocol for detecting CDKN2A mutations has been described 
elsewhere;  most  families  participating  in  the  GenoMEL  con-
sortium were recently evaluated for the types of CDKN2A muta-
tions and associated clinical factors, including age at melanoma 
diagnosis  and  presence  of  multiple  primary  melanomas  in  the 
family (7,30,31). The distribution of the CDKN2A mutations iden-
tified in the 186 families included in this study and their effect on 
p16INK4a  and  p14ARF  proteins  are  shown  in  Supplementary 
Table 1 (available online).
The MC1R genotyping was performed in each center by se-
quencing the entire open reading frame of the single-exon gene in 
both affected patients and unaffected subjects. The methods varied 
slightly between the centers, and examples of methods can been 
found in Vajdic et al. (32) and Kanetsky et al. (33). We checked that 
the distribution of MC1R variants were in Hardy–Weinberg equi-
librium; no departure from Hardy–Weinberg equilibrium at the 
5% significance level was found. The Mendelian inconsistencies of 
the MC1R genotypes were checked using the PedCheck program 
(34), and any inconsistent genotypes were coded as missing data.
Table 1. Cyclin-dependent kinase inhibitor 2A (CDKN2A) mutation carriers from the Melanoma Genetics Consortium (GenoMEL) and 
melanoma affection status in the CDKN2A mutation carriers genotyped for melanocortin-1 receptor (MC1R)* gene
Consortium participant CDKN2A mutation carriers genotyped for MC1R
Consortium center Geographic locale, continent
No. of families;  
(reference)
No. of CDKN2A 
mutation carriers
No. of melanoma  
patients†
No. of unaffected 
subjects‡
Europe        
  Paris France, Europe 27 (16) 95 52 43
  Emilia-Romagna Italy, Europe 4 (21) 8 6 2
  Genoa Italy, Europe 14 (22) 38 26 12
  Leiden the Netherlands, Europe 8 (14) 113 52 61
  Barcelona Spain, Europe 16 (23) 66 30 36
  Lund Sweden, Europe 9 33 17 16
  Stockholm Sweden, Europe 4 (24) 15 5 10
  Glasgow United Kingdom, Europe 13 (25) 27 21 6
  Leeds United Kingdom, Europe 34 (26) 102 61 41
Subtotal   129 497 270 227
North America        
  Boston USA, North America 6 (27) 15 11 4
  NCI USA, North America 16 (15) 136 70 66
  Philadelphia USA, North America 2 10 9 1
  Toronto Canada, North America 15 32 26 6
Subtotal   39 193 116 77
Australia        
  Brisbane Australia 17 (28) 96 76 20
  Sydney Australia 1 (29) 29 11 18
Subtotal   18 125 87 38





‡  The median ages of unaffected subjects at examination were 41 years in Europe, 34 years in North America, and 47 years in Australia.jnci.oxfordjournals.org    JNCI | Articles 1571
Data Collection
Information on familial relationships among members of the same 
family; demographic characteristics (sex; date of birth; and age at 
death and cause of death, if deceased); melanoma status (affected vs 
unaffected) together with confirmation of melanoma diagnosis and 
age at diagnosis; CDKN2A mutation status (no mutation [homozy-
gote wild type] vs presence of a mutation [heterozygote or homozy-
gote for the mutation]) and, in mutation carriers, location of the 
mutation in CDKN2A locus (promoter region, exons 1a, 1b, 2 and 
3, and introns); CDKN2A nucleotide change and subsequent change 
in amino acid in p16INK4a and p14ARF proteins; MC1R genotypes 
(wild-type homozygotes for the consensus sequence, heterozygotes 
or homozygotes for a variant at each position of the sequence where 
an  MC1R  variant  had  been  detected  across  all  participating 
GenoMEL centers), pigmentation characteristics, and nevus phe-
notypes (including hair color, propensity to sunburn, nevus count) 
were obtained from each center using a standardized format based 
on  a  uniform  coding  scheme  across  GenoMEL  centers.  The 
markers of pigmentation and nevus phenotypes used in this study 
were coded as follows—hair color (classified as red, blond, brown, 
black); skin reaction to sun exposure (never burns, sometimes burns, 
usually burns, always burns); and nevus count (none, few, some and 
many nevi). The data received from each center were integrated 
into a common dataset using the Statistical Analysis System (SAS) 
software (version 9.1, developed by SAS Institute Inc, Cary, NC).
Statistical Analysis
Associations  between  MC1R  variants  and  melanoma  affection 
status (affected vs unaffected) were evaluated in CDKN2A muta-
tion  carriers  using  the  generalized  estimating  equations  (GEE) 
method  to  take  into  account  familial  dependences.  The  GEE 
method, a semiparametric regression method, specifies the rela-
tionship between the disease outcome (melanoma affection status) 
and  predictor  variables  (eg,  MC1R  variants,  host  phenotypes) 
through a link function and takes into account the correlations 
among disease outcomes of family members through a correlation 
matrix. We used the logit link function and exchangeable correla-
tion matrix, which assumes equal correlations among the disease 
outcomes in family members, to estimate odds ratios (ORs) and 
95% confidence intervals (CIs). All analyses were adjusted for sex 
and age at examination as a continuous variable. We used age at 
examination for all subjects rather than age at diagnosis for mela-
noma patients because some host-related phenotypes like number 
of nevi vary with age and were assessed at time of examination. 
Tests  of  association  between  melanoma  and  predictor  variables 
(MC1R variables as defined below and/or host phenotypes) were 
based on two-sided generalized score statistics.
Before conducting the association analysis of melanoma with 
MC1R variants, we estimated the frequency of each MC1R variant 
from individual genotypic data in CDKN2A mutation carriers (af-
fected  melanoma  patients,  unaffected  subjects,  and  all  subjects) 
from each continent, as well as all three continents combined. The 
frequent  variants  were  those  that  had  an  estimated  frequency 
greater than or equal to 5% in all CDKN2A mutation carriers from 
at  least  one  continent  and  in  all  three  continents  (Table  2; 
Supplementary Table 2, available online). These frequent variants 
were the only ones that were analyzed individually.
We first investigated associations between melanoma and each 
frequent nonsynonymous MC1R variant individually by comparing 
carriage of at least one variant (homozygotes and heterozygotes 
pooled) to homozygosity for the MC1R consensus sequence (refer-
ence  category).  Because  many  MC1R  variants  were  too  rare  to 
examine  their  individual  association  with  melanoma  risk  in 
CDKN2A carriers, all nonsynonymous variants were grouped in 
various ways to make the following comparisons—carriers of any 
MC1R variant compared with homozygosity for the MC1R con-
sensus sequence; carriers of multiple MC1R variants (1, ≥2 vari-
ants)  compared  with  homozygosity  for  the  MC1R  consensus 
sequence;  and  carriers  of  specific  types  of  MC1R  variants  (1 
NRHC variant, 1 RHC variant, ≥2 NRHC variants, ≥2 RHC var-
iants, or carriers of both RHC and NRHC variants) compared 
with MC1R consensus sequence. The RHC variants included four 
MC1R variants (R151C, R160W, D294H, and D84E), which have 
been consistently reported to be associated with RHC and light 
skin  color;  all  other  nonsynonymous  variants  were  coded  as 
NRHC.
Generalized score tests for association of melanoma risk with 
carriage of any MC1R variant and number of variants were con-
ducted  for  each  geographic  locale  separately,  whereas  tests  for 
other MC1R variables (individual variants and types of variants) 
were conducted by continent (ie, pooling locales within Europe) 
because  of  small  sample  size  in  individual  European  countries. 
Pooled analyses of all locales within Europe and across continents 
were carried out by introducing a locale indicator variable in the 
regression  model  between  disease  outcome  and  predictor  vari-
ables. This locale adjustment in the regression model can correct 
for potential population stratification because the locale variable 
was country specific for European mutation carriers in all analyses, 
whereas  it  was  continent  specific  for  North  American  and 
Australian mutation carriers because they were all of European 
ancestry and more than 70% were recruited from a single center, 
respectively (15,28). The homogeneity in the association of mela-
noma with any of the MC1R variables analyzed among geographic 
locales (as defined in the GenoMEL subjects paragraph) was tested 
by introducing MC1R variable × locale interaction terms in the 
regression  model  between  melanoma  and  the  MC1R  variable, 
which also included sex, age at examination, and the locale indi-
cator variable. These interaction terms, which are equal to zero 
under the null hypothesis of homogeneity of the association of 
MC1R  variable  with  melanoma  across  geographic  locales,  were 
tested using a generalized score test which follows a x
2 distribution 
with number of degrees of freedom equal to number of locales 
minus 1 for a given MC1R variable category. It must be noted that, 
for MC1R variables with only one category (eg, presence of a given 
MC1R variant or presence of any MC1R variant), there was only 
one interaction term per geographic locale, whereas for MC1R 
variables with more than one category (eg, number of MC1R vari-
ants and types of variants), there was one interaction term between 
each MC1R variable category and each geographic locale. We also 
used the Cochran Q test (35) to test for homogeneity of the esti-
mates of the odd -ratios associated with each of the MC1R variables 
among European, North American, and Australian mutation car-
riers. We also investigated whether the associations of the frequent 
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differed according to the type of CDKN2A mutations (mutations 
affecting  p16INK4a  protein  only  vs  mutations  affecting  both 
p16INK4a and p14ARF proteins). The homogeneity of the odds 
ratios associated with these MC1R variables by type of CDKN2A 
mutations was tested by the Cochran Q test.
To investigate whether MC1R variants and host phenotypes 
were jointly associated with melanoma risk, we first assessed the 
association of each host phenotype alone with melanoma risk and 
then jointly examined the associations of MC1R variants and each 
phenotype and the associations of MC1R variants and all pheno-
types with melanoma risk. These analyses were based on the GEE 
method,  as  described  above.  We  considered  various  regression 
models between the melanoma affection status and predictor vari-
ables depending on the predictors included in the model: each host 
phenotype or all host phenotypes, with and without MC1R vari-
ants, while always adjusting for sex, age at examination, and geo-
graphic locale in the model. Regarding MC1R, we included in the 
regression model each frequent variant individually or the number 
of  MC1R  variants.  The  host  phenotypes  were  dichotomized  as 
follows—hair color (blond or red vs dark or brown), propensity to 
sunburn (usually or always burns vs sometimes or never burns) and 
nevus count (some or many nevi vs none or few nevi). Regarding 
hair color, the number of subjects with red hair (total, 57 subjects; 
affected, 47 subjects; unaffected, 10 subjects) precluded evaluation 
of red hair alone. Tests of associations between melanoma and 
each variable (host phenotypes and/or MC1R variants) were based 
on generalized score tests, as described before.
We also investigated whether the age at diagnosis of melanoma 
was influenced by MC1R variants. We estimated the median ages 
at melanoma diagnosis for each category of MC1R variables in 
melanoma patients from each continent and from all three conti-
nents. The nonparametric Jonckheere–Terpstra test was used to 
test the null hypothesis of no difference in the ages at diagnosis of 
melanoma across different categories of MC1R variables, against 
the alternative hypothesis of a change in age at diagnosis with the 
presence of any variant, presence of individual frequent variants, or 
as the number or number and types of MC1R variants increased.
All analyses were carried out using the SAS software (version 
9.1). All statistical tests were two-sided.
Results
GenoMEL  Participants  Included  in  the  Study  and  MC1R 
Variants
A total of 815 CDKN2A mutation carriers genotyped for MC1R 
were available for this study (Table 1). The percentage of mela-
noma patients (affected) was 54.3% in Europe, 60.1% in North 
America, and 69.6% in Australia. The median ages at examination 
among affected and unaffected CDKN2A mutation carriers were 
47 and 41 years, respectively, in Europe; 42 and 34 years, respec-
tively, in North America; and 54 and 47 years, respectively, in 
Australia. Among the melanoma patients, there were 43% men in 
Europe, 51% men in North America, and 54% men in Australia, 
whereas the percentages of men were 48%, 35%, and 47%, respec-
tively, in unaffected subjects. No statistically significant difference 
in these proportions of men among affected melanoma patients   
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statistically significant difference in the median age at diagnosis of 
melanoma: 36 years in Europe, 31 years in North America, and 34 
years in Australia (P = .08) was observed.
We estimated the frequency of each MC1R variant in CDKN2A 
mutation carriers from each continent and from all three conti-
nents (Table 2; details provided in Supplementary Table 2, avail-
able online). A total of 33 variants of MC1R were detected; 23 
variants  corresponded  to  nonsynonymous  amino  acid  changes, 
eight variants corresponded to synonymous amino acid changes, 
and  two  variants  corresponded  to  insertions.  All  subsequent 
analyses were restricted to nonsynonymous variants. Four nonsyn-
onymous  variants  (V60L,  V92M,  R151C,  and  R160W)  were 
observed at a frequency greater than or equal to 5% in at least one 
continent and all three continents in all mutation carriers (Table 2) 
as well as in affected and unaffected carriers (Supplementary Table 2, 
available online). The frequency of these variants did not differ 
statistically significantly across continents in unaffected mutation 
carriers (P > .20).
Associations of MC1R Variants With Melanoma Risk in 
CDKN2A Mutation Carriers
We first assessed the association of each of the four most frequent 
MC1R  variants  with  melanoma  risk  in  CDKN2A  carriers.  Both 
RHC (R151C and R160W) and NRHC (V60L and V92M) vari-
ants  were  associated  with  increased  melanoma  risk,  but  with 
varying strengths in different continents (Table 3). In Europe, this 
association was statistically significant for each variant, and the 
strongest  association  was  noted  for  RHC  variants,  followed  by 
NRHC variants (.0002 ≤ P ≤ .03). In North America, the associa-
tion with increased melanoma risk reached statistical significance 
with R151C, R160W, and V92M variants (.05 ≤ P ≤ .02), whereas 
in Australia, the association reached statistical significance with 
V60L (P = .009) and R151C (P = .03) variants. The association of 
any of these MC1R variants with melanoma risk did not show evi-
dence  of  heterogeneity  across  continents  (Phomogeneity  ≥  .09).  The 
pooled estimates of the odds ratios adjusted for age, sex, and locale 
were always higher than 2.0 and were lowest for V92M (OR = 2.43, 
95% CI = 1.45 to 4.06) and highest for R151C (OR = 4.68, 95% 
CI = 2.52 to 8.68).
We carried out subsequent analyses by pooling all nonsynony-
mous variants in different ways—pooling all of them in one cate-
gory (presence of any variant), pooling them according to their 
number  (1,  ≥2  variants),  and  pooling  them  according  to  their 
number and types (number of RHC and NRHC variants). When 
all nonsynonymous MC1R variants were pooled (Table 3), carrying 
at least one variant was associated with increased melanoma risk in 
all three continents (.0006 ≤ P ≤ .05). Some variation in the increase 
in  melanoma  risk  was  observed  within  Europe  (Supplementary 
Table  3,  available  online).  The  highest  increases  in  risk  were 
observed in France, Spain, and Sweden (.02 ≤ P ≤ .04), whereas the 
odds ratio was close to unity in Italy, the country with the smallest 
sample size (Supplementary Table 3, available online). Nevertheless, 
tests for heterogeneity in the association of at least one MC1R var-
iant with melanoma risk among geographic locales were not statis-
tically significant (P = .11 within Europe; and P = .16 across all 
continents). In CDKN2A mutation carriers from all three conti-
nents, the presence of at least one MC1R variant was associated 
with a threefold increase in melanoma risk (OR = 3.05, 95% CI = 
1.99 to 4.67). We then investigated whether there was an increase 
in  melanoma  risk  associated  with  an  increase  in  the  number  of 
MC1R  variants.  The  increase  in  the  number  of  MC1R  variants 
showed a consistent increase in melanoma risk in CDKN2A muta-
tion  carriers  from  Europe,  North  America,  and  Australia  (for 
Europe, Ptrend = 6.25 × 10
26; for North America, Ptrend = .01; and for 
Australia,  Ptrend  =  .03)  (Table  3).  This  increase  in  risk  with  the 
increase in numbers of MC1R variants was seen in all European 
countries except Italy, where there was no increase in melanoma 
risk associated with either one MC1R variant or at least two variants 
(Supplementary Table 3, available online), and in Sweden, where 
the increase in melanoma risk associated with one variant was sim-
ilar  to  the  increase  in  risk  associated  with  at  least  two  variants 
(Supplementary Table 3, available online). No statistically signifi-
cant  heterogeneity  for  the  increase  in  melanoma  risk  with  the 
increase in number of MC1R variants was detected either across 
European  countries  (Phomogeneity  =  .14)  or  across  all  continents 
(Phomogeneity = .23). Overall, the risk associated with at least two MC1R 
variants was 2.6-fold higher than the risk associated with only one 
variant (OR = 5.83 [95% CI = 3.60 to 9.46] vs 2.25 [95% CI = 1.44 
to 3.52]; Ptrend = 1.86 × 10
28). Next, we explored whether there was 
an increase in melanoma risk with both the number and types of 
MC1R variants (RHC variants and NRHC variants). We observed 
that in all continents an increase in melanoma risk was associated 
with an increase in number of variants and, mostly, when the geno-
type  included  RHC  variants  (Table  3).  The  association  with 
number  and  types  of  MC1R  variants  was  homogeneous  among 
continents  (Phomogeneity  =  .07).  The  odds  ratios  estimated  from  all 
continents showed that there was a more than fivefold increase in 
melanoma  risk  in  CDKN2A  mutation  carriers  with  at  least  two 
RHC  variants  compared  with  one  NRHC  variant  (OR  =  11.78 
[95%  CI  =  5.34  to  26.02]  vs  2.08  [95%  CI  =  1.28  to  3.40], 
respectively).
Because there was no statistically significant evidence for het-
erogeneity in the association of any of the studied MC1R variables 
with the melanoma risk across all geographic locales, we investi-
gated whether the association of melanoma risk with individual 
MC1R  variants  and  number  of  variants  differed  by  the  type  of 
CDKN2A  mutation  in  all  CDKN2A  mutation  carriers  from  all 
three  continents,  while  adjusting  for  age,  sex,  and  geographic 
locale (Table 4). Overall, the point estimates of the odds ratios 
associated with each MC1R variant, except R160W, were higher 
when  the  CDKN2A  mutations  affected  the  p16INK4a  protein 
alone,  than  when  they  affected  both  p16INK4a  and  p14ARF 
proteins. However, the confidence intervals were wide and tests of 
homogeneity  for  any  MC1R  variant  according  to  the  type  of 
CDKN2A mutation were not significant (P ≥ .09). Similar results 
were obtained when the analysis was done with the number of 
MC1R variants (Table 4).
Joint Associations of MC1R Variants and Host Phenotypes 
With Melanoma Risk in CDKN2A Mutation Carriers
Next we assessed the joint associations of MC1R variants and host 
phenotypes with melanoma risk in all CDKN2A mutation carriers 
from all three continents. We confirmed that, in the unaffected 
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associated with red or blond hair color (P ≤ .016) and the R151C 
(P = .002), V60L (P = .03), and V92M (P = .03) variants were statis-
tically significantly associated with sunburn, but no variant was as-
sociated with high numbers of nevi (data not shown). Table 5 shows 
that when each host phenotype was analyzed separately, hair color, 
sunburn, and high numbers of nevi were statistically significantly 
associated with increase in melanoma risk, while adjusting for age, 
sex, and geographic locale (for red or blond hair color: OR = 3.30, 
95% CI = 1.98 to 5.52; for usually or always burns: OR = 2.10, 95% 
CI = 1.39 to 3.17; and for high numbers of nevi: OR = 3.05, 95% 
CI = 1.95 to 4.78). In the presence of host phenotypes, analyzed 
individually or jointly, the increase in melanoma risk with any one 
of the four frequent MC1R variants remained statistically signifi-
cant (Table 5). Hair color showed an additional association with 
melanoma risk with most variants (.01 ≤ P ≤ .07), whereas sunburn 
was  only  marginally  statistically  significant  (P  ≥  .03)  (Table  5). 
Moreover, an increase in the number of nevi contributed indepen-
dently to melanoma risk (.005 ≤ P ≤ .02). We obtained similar 
results when the number of variants was analyzed. A statistically 
significant increase in melanoma risk with number of variants in the 
presence  of  each  host  phenotype  or  with  all  phenotypes  was 
observed (for one variant, .01 ≤ P ≤.02; and for at least two variants, 
1.6 × 10
25 ≤ P ≤ .0001). Hair color and number of nevi, both sepa-
rately  and  together,  showed  statistically  significant  associations 
with melanoma risk in addition to the number of MC1R variants 
(for hair color, P ≤ .006; and for nevi, P ≤ 2.6 × 10
25), whereas 
the association with sunburn was no longer statistically significant 
(P ≥ .11). Because MC1R variants are much more strongly associ-
ated with red hair than with blond hair in the general population 
(36,37), analyses were repeated after excluding the 57 CDKN2A 
mutation carriers with red hair and showed associations between 
MC1R variants and hair color with melanoma risk similar to those 
shown in Table 5, indicating that blond hair was the major deter-
minant of the odds ratios that were previously obtained when sub-
jects with red hair were included in the analysis (data not shown). 
Further stratified analysis based on hair color showed that the sta-
tistically significant increase in melanoma risk that was associated 
with individual MC1R variants or number of variants was limited to 
subjects with brown or black hair (Supplementary Table 4, avail-
able online), thus confirming the role of MC1R beyond that due to 
pigmentation.
Association of MC1R Variants With Age at Diagnosis of 
Melanoma
Finally, to assess whether MC1R variants have an influence on age 
at diagnosis of melanoma, we examined the median ages at diagno-
sis of melanoma according to various categories of MC1R variables 
(individual variants, presence of any variant, number of variants, 
and number and types of variants). As shown in Table 6, there was 
a slight decrease in age at diagnosis in CDKN2A mutation carriers 
with presence of R151C or R160W variants or with increase in 
number and types of variants. This decrease in age at diagnosis 
reached marginally statistical significance in CDKN2A mutation 
carriers from Europe (.02 ≤ P ≤ .05), or when the CDKN2A muta-
tion carriers were pooled across all continents (.008 ≤ P ≤ .06).
Discussion
This study investigated the associations of MC1R variants with 
melanoma risk in 815 CDKN2A mutation carriers from 186 fam-
ilies  that  participated  in  15  GenoMEL  centers  across  Europe, 
North America, and Australia. The included families had at least 
two cutaneous melanoma patients and the presence of a germline 




CDKN2A mutations that altered 
p16INK4a protein only
CDKN2A mutations that altered both 
p16INK4a and p14ARF proteins
Phomogeneity║
No. of participants,  
affected/unaffected† OR (95% CI)‡ P§
No. of participants,  
affected/unaffected† OR (95% CI)‡ P§
Individual MC1R 
    variants
           
  V60L 82/59 5.98 (2.56 to 13.97) .0005 103/114 2.70 (1.62 to 4.49) .0007 .11
  V92M 53/55 4.38 (1.95 to 9.84) .0006 85/111 2.18 (1.14 to 4.17) .03 .19
  R151C 80/53 10.41 (4.59 to 23.57) 7.04 × 1025 122/105 4.04 (1.90 to 8.59) .0002 .09
  R160W 45/50 4.12 (1.71 to 9.95) .002 100/101 4.40 (2.14 to 9.04) .004 .91
No. of MC1R 
    variants
195/121     263/214    
  1 variant   3.63 (1.63 to 7.64) .003   1.91 (1.09 to 3.33) .03 .15
  ≥2 variants   8.38 (3.82 to 18.36) 2.15 × 10
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by far the largest analysis of CDKN2A mutations carriers to date 
that explored the associations of MC1R variants with melanoma 
risk alone, and jointly, with host phenotypes. Our study showed 
that both RHC and NRHC variants were statistically signifi-
cantly  associated  with  melanoma  risk  in  CDKN2A  mutation 
carriers across all three continents, strengthening the fact that 
the melanoma risk is not restricted to red hair color variants The 
joint analysis of MC1R variants and host phenotypes (hair color, 
propensity  to  sunburn,  number  of  nevi),  showed  that,  in 
CDKN2A mutation carriers, MC1R variants have an association 
with melanoma development beyond that due to pigmentation. 
We also found that, in addition to MC1R variants, both hair 
color and high numbers of nevi were associated with melanoma 
risk.
A total of 23 nonsynonymous MC1R variants were detected in 
affected  and  unaffected  CDKN2A  mutation  carriers  of  the  186 
melanoma-prone  families,  and  four  of  these  variants  (V60L, 
V92M, R151C, and R160W) showed a frequency more than 5% in 
these mutation carriers across all continents. Despite the ascertain-
ment of the families through at least two melanoma patients, the 
frequencies of these four variants in unaffected CDKN2A mutation 
carriers were similar to those reported in control groups from the 
same populations (12,18).
We found that both RHC and NRHC variants were associated 
with statistically significantly increased melanoma risk in CDKN2A 
mutation  carriers,  whereas  a  recent  meta-analysis  of  melanoma 
case–control studies reported that most MC1R variants, except the 
most frequent NRHC variants, V60L and V92M, were associated 
with statistically significantly increased melanoma risk (12). The 
meta-analysis showed some evidence of heterogeneity for the asso-
ciation of V60L variant with melanoma that seemed to be because 
of higher risk in Mediterranean populations (12). The sample sizes 
in the current study did not allow investigation of the association 
of specific variants by country; however, an increased melanoma 
risk associated with V60L variant was found in all three continents. 
The regulation of the pigmentation process by MC1R, stimulated 
by the a-melanocyte–stimulating hormone (a-MSH), is mediated 
by  its  ability  to  increase  intracellular  cyclic  AMP  levels,  which 
triggers downstream signaling events (11). Functional studies have 
shown that the V60L variant has a decreased ability to stimulate 
cyclic AMP levels, compared with wild-type MC1R, as observed 
with the RHC variants (38,39). Although the V92M variant was 
reported to have an ability to increase the cylic AMP levels similar 
to that of the wild-type MC1R (38,39), it was found to have a 
reduced affinity for the MC1R ligand, a-MSH, by other studies 
(40,41). Moreover, the V92M variant may also be impaired in the 
desensitization and internalization of MC1R, two mechanisms that 
occur  after  exposure  of  G  protein–coupled  receptors,  such  as 
MC1R,  to  their  ligands  to  arrest  G  protein  signaling  (39,42). 
Further investigation of the functional role of MC1R variants in 
presence  of  CDKN2A  mutation  would  be  worth  performing  to 
explore how the function of MC1R variants is altered.
The increase in melanoma risk with increase in number of MC1R 
variants  confirms  previous  observations  in  CDKN2A  mutation–
positive families (14–16). We observed this increased risk across all 
continents, except Sweden and Italy in Europe. The small number 
of Swedish CDKN2A mutation carriers is likely to have produced 
the results in these subjects because a recent Swedish case–control 
study reported an increase in melanoma risk with an increase in 
the number of MC1R variants, and the risk was even higher in 
familial cases (43). Although the Italian CDKN2A mutation car-
riers in our study did not show an association between MC1R and 
melanoma risk, previous studies of unselected case patients and 
control subjects from different regions of Italy showed statistically 
significant  associations  between  MC1R  variants  and  melanoma 
risk (21,44,45). However, the results of our analysis in CDKN2A 
mutation carriers were also consistent with many previous case–
control studies from various populations that showed an increased 
risk with multiple MC1R variants (21,43,46–49). An increase in 
melanoma risk with increase in the number of MC1R variants was 
also reported in a recent meta-analysis of the association between 
MC1R variants and melanoma risk in CDKN2A mutation carriers 
(50). It must be noted that the meta-analysis of published results 
was conducted on a much smaller sample size compared with the 
present analysis of raw genotypic and phenotypic data (96 vs 186 
families) and did not address several points presented here, in-
cluding the association of MC1R variants by type of CDKN2A 
mutation and the joint associations of MC1R variants and host 
phenotypes with melanoma risk.
When examining the number and types of MC1R variants, we 
observed that the increase in melanoma risk was generally higher 
in the presence of RHC variants. The classification of MC1R var-
iants into RHC and NRHC was primarily based on the strength of 
association of these variants with red hair in populations of Celtic 
origin (17). This classification has been evolving over time and is 
not entirely uniform across studies investigating MC1R variants 
and the melanoma risk. We have chosen to restrict our categoriza-
tion  of  RHC  variants  to  the  four  MC1R  variants  consistently 
defined as RHC variants (R151C, R160W, D294H, and D84E).
The association of MC1R variants with melanoma risk may vary 
with the type of CDKN2A mutations. Indeed, a molecular basis for 
the link between CDKN2A and MC1R has been provided by in 
vitro studies that showed that the increased expression of p16INK4a 
after exposure to ultraviolet radiation is potentiated by a-MSH 
through its binding to MC1R (51). In our analysis, the associations 
of MC1R variants with melanoma risk did not differ statistically 
significantly depending on whether CDKN2A mutations altered 
only  the  p16INK4a  protein  or  both  p16INK4a  and  p14ARF 
proteins.
It is not fully resolved whether the increased melanoma risk at-
tributed to the MC1R variants is distinct from their association with 
pigmentation characteristics. Case–control studies have indicated 
that  part  of  the  association  between  melanoma  risk  and  MC1R 
variants remains after stratification of phenotypic features suggest-
ing that the association of MC1R is not exerted entirely through 
pigmentation  (21,46–48).  However,  this  issue  has  been  scarcely 
investigated  in  CDKN2A  mutation–positive  families  (15,16,21). 
This study showed that all four frequent MC1R variants, V60L, 
V92M, R151C, and R160W, were still associated with a statistically 
significantly increased melanoma risk, while adjusting for hair color 
or sunburn. Further stratified analysis based on hair color showed 
that  the  statistically  significantly  increase  in  risk  was  limited  to 
subjects with brown or black hair, in agreement with a recent case–
control study (52). These results strengthen the hypothesis that 1580   Articles | JNCI  Vol. 102, Issue 20  |  October 20, 2010
MC1R variants may have a role in carcinogenesis in addition to its 
influence on pigment variation. Experimental (in vitro) studies have 
shown that, besides its role in pigmentation, a-MSH, which binds 
to  MC1R,  is  involved  in  anti-apoptotic  DNA  repair  and  anti- 
inflammatory pathways (53–56). The additional association of hair 
color  with  melanoma  risk  is  in  agreement  with  results  from 
genome-wide association studies that have identified several loci 
influencing pigmentation phenotypes (36,37). Our study also dem-
onstrates that having high numbers of nevi was associated with a 
statistically significantly increased melanoma risk in CDKN2A mu-
tation carriers, independently of MC1R variants. A recent genome-
wide  association  study  (57),  carried  out  by  GenoMEL,  in 
CDKN2A-negative melanoma case patients and control subjects, 
identified independent associations of three loci with melanoma 
risk—16q24, encompassing MC1R; 11q14–q21, encompassing the 
tyrosinase  pigmentation  gene  (TYR);  and  9p21,  adjacent  to 
CDKN2A  and  the  methylthioadenosine  phosphorylase  (MTAP) 
genes  (CDKN2A/MTAP).  The  CDKN2A/MTAP  locus  was  con-
comitantly characterized as a nevus gene (58). Further investigation 
of  the  TYR  and  CDKN2A/MTAP  loci  in  families  segregating 
CDKN2A mutations will allow assessment of whether common var-
iants of these genes also modify penetrance of CDKN2A deleterious 
mutations.
Our analysis may have a few limitations. A slight decrease in age 
at melanoma diagnosis, which only reached statistical significance 
in the largest sample of European CDKN2A mutation carriers and 
in mutation carriers from all three continents, was observed with 
the presence of RHC variants and as the number and types of 
variants increased. A decrease in age at melanoma diagnosis with 
increasing number of MC1R variants was previously reported to be 
mostly statistically significant in melanoma patients with multiple 
primary melanomas (15,22). Any information on the occurrence of 
single or multiple primary melanoma was not available for this 
analysis; however, we plan to investigate in the near future whether 
the association of MC1R with age at melanoma diagnosis differs in 
single vs multiple primary melanoma. The association of MC1R 
variants with melanoma risk was currently assessed by comparing 
affected  and  unaffected  family  members  using  an  analytical 
method that accounts for the familial dependence and prevents 
inflation of the type I error rate (59). It should be noted that the 
odds ratios presented here are estimates of association in families 
similar to the sampled families and cannot be extrapolated to the 
general population. In all analyses, we used age at examination 
rather than age at diagnosis of melanoma because the host pheno-
types that were examined jointly with MC1R variants vary over 
time and were measured at the time of examination. However, 
repeating the analyses using age at diagnosis of melanoma patients 
produced similar results for the association of MC1R variants and 
melanoma risk (data not shown).
In conclusion, this study shows that melanoma risk in CDKN2A 
mutation  carriers  is  modified  by  multiple  factors  that  include 
MC1R variants, pigmentation, and nevus phenotypes. Investigation 
of other modifying genes, such as those identified by genome-
wide  association  studies,  may  help  clarify  the  complex  mecha-
nisms  leading  to  familial  melanoma.  Such  studies  may  have 
important consequences for improving melanoma risk assessment 
in families.
Appendix
The Melanoma Genetics Consortium (GenoMEL; http://www.genomel.org) in-
cluded the following participating groups:
Europe
The participants of GenoMEL in Paris, France: Florence Demenais, Hamida 
Mohamdi, Valérie Chaudru, Eve Corda, Patricia Jeannin, and Eve Maubec 
(Inserm U946 and Université Paris Diderot, Fondation Jean Dausset-CEPH, 
Paris, France), Marie-Françoise Avril (AP-HP, Hôpital Cochin, Service de 
Dermatologie, Université Paris 5, Paris, France), Brigitte Bressac-de Paillerets, 
Fabienne  Lesueur,  and  Mahaut  de  Lichy  (Département  de  Génétique 
Moléculaire, Institut de Cancérologie Gustave Roussy, Villejuif, France).
The participants of GenoMEL in Emilia-Romagna, Italy: Maria Teresa Landi 
(Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, 
National Cancer Institute, National Institutes of Health, Department of Health 
and  Human  Services,  Bethesda,  MD),  Donata  Calista,  Giorgio  Landi,  Paola 
Minghetti,  Daniela  Capirossi,  Pier  Alberto  Bertazzi,  and  Fabio  Arcangeli 
(Dermatology Unit, Maurizio Bufalini Hospital, Cesena, Italy). 
The  participants  of  GenoMEL  in  Genoa,  Italy:  Giovanna  Bianhi-Scarrà, 
Lorenza  Pastorino,  Linda  Battistuzzi,  William  Bruno,  Sara  Gargiulo,  Paola 
Ghiorzo,  Sara  Gliori,  Sabina  Nasti,  Paola  Origone,  and  Paola  Queirolo 
(Department of Oncology, Biology and Genetics, University of Genoa, Italy; 
Laboratory  of  Genetics  of  Rare  Hereditary  Cancers,  San  Martino  Hospital, 
Genoa, Italy).
The participants of GenoMEL in Leiden, the Netherlands: Nelleke A. Gruis, 
Frans A van Nieuwpport, Wilma Bergman, Pieter van der Velden, and Leny van 
Mourik  (Department  of  Dermatology,  Leiden  University  Medical  Centre, 
Leiden, the Netherlands).
The participants of GenoMEL in Barcelona, Spain: Paula Aguilera, Celia 
Badenas, Cristina Carrera, Remedios Cervera, Francisco Cuellar, Daniel Gabriel, 
Melinda Gonzalez, Pablo Iglesias, Josep Malvehy, Rosa Marti-Laborda, Montse 
Mila, Zighe Ogbah, Joan-Anton Puig Butille, and Susana Puig (Dermatology 
Department,  Melanoma  Unit,  Hospital  Clinic,  IDIBAPS  and  CIBER  de 
Enfermedades Raras, Barcelona, Spain) and other members of the Melanoma 
Unit: Llúcia Alós, Ana Ancero, Pedro Arguís, Antonio Campo, Teresa Castel, 
Carlos  Conill,  Jose  Palou,  Ramon  Rull,  Marcelo  Sánchez,  Sergi  Vidal-Sicart, 
Antonio Vilalta, and Ramon Vilella (Dermatology Department, Melanoma Unit, 
Hospital Clinic, IDIBAPS and CIBER de Enfermedades Raras, Barcelona, Spain).
The participants of GenoMEL in Lund, Sweden: Håkan Olsson, Christian 
Ingvar, Kari Nielsen, Anna Måsbäck, Katja Harbst, Göran. Jönsson, Åke Borg 
(Departments of Surgery and Oncology, Lund University Hospital, Lund, Sweden).
The  participants  of  GenoMEL  in  Stockholm,  Sweden:  Veronica  Höiom, 
Johan Hansson, Rainer Tuominen, Diana Lindén (Department of Oncology-
Pathology,  Karolinska  Institutet,  Karolinska  University  Hospital  Solna, 
Stockholm, Sweden).
The participants of GenoMEL in Glasgow, United Kingdom: Rona Mackie, 
Julie Lang (Departments of Medical Genetics and Public Health, University of 
Glasgow, United Kingdom).
The participants of GenoMEL in Leeds, United Kingdom: Julia A Newton 
Bishop, Paul Affleck, Jennifer H Barrett, D Timothy Bishop, Jane Harrison, Mark 
M  Iles,  Juliette  Randerson-Moor,  Mark  Harland,  John  C  Taylor,  Linda 
Whittaker,  Kairen  Kukalizch,  Susan  Leake,  Birute  Karpavicius,  Sue  Haynes, 
Tricia  Mack,  May  Chan,  and  Yvonne  Taylor  (Section  of  Epidemiology  and 
Biostatistics,  Leeds  Institute  of  Molecular  Medicine,  Cancer  Research  UK 
Clinical  Centre  at  Leeds,  St  James’s  University  Hospital,  Leeds,  United 
Kingdom).
North America
The participants of GenoMEL in Boston, United States: Hensin Tsao, Ching-Ni 
Jenny  Njauw  (Wellman  Center  for  Photomedicine,  MGH  Melanoma  and 
Pigmented Lesion Center, Massachusetts General Hospital, Boston, MA).
The participants of GenoMEL at NCI, United States: Alisa M. Goldstein, 
Margaret A. Tucker, Xiaohong R. Yang (Genetic Epidemiology Branch, Division 
of  Cancer  Epidemiology  and  Genetics,  National  Cancer  Institute,  National 
Institutes of Health, Department of Health and Human Services, Bethesda, MD).
The participants of GenoMEL in Philadelphia, United States: Peter Kanetsky, 
David Elder,Patricia Van Belle, Michael Ming, Nandita Mitra, Althea Ruffin, jnci.oxfordjournals.org    JNCI | Articles 1581
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